Even after anti-androgen therapy, docetaxel remains useful in prostate cancer …

Even after anti-androgen therapy, docetaxel remains useful in prostate cancer …

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate

(Visited 6 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.